神经科

订阅

MedSci主页 / 所有栏目 / 神经科

2019年帕金森病及相关疾病世界大会（IAPRD）：INGREZZA和Opicapone的全新数据

2019-06-12 不详 网络

INGREZZA帕金森病IAPRD迟发性运动障碍
关注

Neurocrine生物医学近日宣布，它将在IAPRD上展示其两项运动障碍实验的数据，以验证INGREZZA（缬氨苄嗪，美国FDA批准用于治疗迟发性运动障碍的首款药物）和opicapone（帕金森病研究性辅助治疗药物）的有效性和安全性。

Neurocrine生物医学近日宣布，它将在IAPRD上展示其两项运动障碍实验的数据，以验证INGREZZA（缬氨苄嗪，美国FDA批准用于治疗迟发性运动障碍的首款药物）和opicapone（帕金森病研究性辅助治疗药物）的有效性和安全性。

迟发性运动障碍（TD）是长期使用多巴胺受体阻滞剂后迟发发作的一种多动性运动障碍，这些阻滞剂主要是抗精神病药物以及止吐药甲氧氯普胺。TD的临床表现多种多样，包括舞蹈病、手足徐动症、肌张力障碍、静坐不能、刻板行为，罕见情况下还包括震颤。


原始出处：

http://www.firstwordpharma.com/node/1646844#axzz5qOw0cfEI

本文系梅斯医学（MedSci）原创编译整理，转载需授权!

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1898035, encodeId=6c7c1898035fa, content=<a href='/topic/show?id=832c404308' target=_blank style='color:#2F92EE;'>#CAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4043, encryptionId=832c404308, topicName=CAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Sat May 09 18:45:00 CST 2020, time=2020-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1933978, encodeId=901d19339e834, content=<a href='/topic/show?id=5f6598551d' target=_blank style='color:#2F92EE;'>#INGREZZA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9855, encryptionId=5f6598551d, topicName=INGREZZA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512d422, createdName=canlab, createdTime=Sun May 10 05:45:00 CST 2020, time=2020-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=367642, encodeId=d1ed36e642aa, content=向挑战病魔的科研人员致敬！向挑战病魔的科研人员致敬, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e5171668917, createdName=坚强007, createdTime=Wed Jun 12 17:04:28 CST 2019, time=2019-06-12, status=1, ipAttribution=)]
    2020-05-09 smlt2008

    #CAP#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1898035, encodeId=6c7c1898035fa, content=<a href='/topic/show?id=832c404308' target=_blank style='color:#2F92EE;'>#CAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4043, encryptionId=832c404308, topicName=CAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Sat May 09 18:45:00 CST 2020, time=2020-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1933978, encodeId=901d19339e834, content=<a href='/topic/show?id=5f6598551d' target=_blank style='color:#2F92EE;'>#INGREZZA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9855, encryptionId=5f6598551d, topicName=INGREZZA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512d422, createdName=canlab, createdTime=Sun May 10 05:45:00 CST 2020, time=2020-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=367642, encodeId=d1ed36e642aa, content=向挑战病魔的科研人员致敬！向挑战病魔的科研人员致敬, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e5171668917, createdName=坚强007, createdTime=Wed Jun 12 17:04:28 CST 2019, time=2019-06-12, status=1, ipAttribution=)]
    2020-05-10 canlab

    #INGREZZA#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1898035, encodeId=6c7c1898035fa, content=<a href='/topic/show?id=832c404308' target=_blank style='color:#2F92EE;'>#CAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4043, encryptionId=832c404308, topicName=CAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Sat May 09 18:45:00 CST 2020, time=2020-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1933978, encodeId=901d19339e834, content=<a href='/topic/show?id=5f6598551d' target=_blank style='color:#2F92EE;'>#INGREZZA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9855, encryptionId=5f6598551d, topicName=INGREZZA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512d422, createdName=canlab, createdTime=Sun May 10 05:45:00 CST 2020, time=2020-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=367642, encodeId=d1ed36e642aa, content=向挑战病魔的科研人员致敬！向挑战病魔的科研人员致敬, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e5171668917, createdName=坚强007, createdTime=Wed Jun 12 17:04:28 CST 2019, time=2019-06-12, status=1, ipAttribution=)]
    2019-06-12 坚强007

    向挑战病魔的科研人员致敬！向挑战病魔的科研人员致敬

    0